Vaccinex (VCNX) announced the signing of several proprietary project agreements with Amgen, Merck, Chugai, Absci, Gigagen, Merus, Soleil, ...

Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.